Injectable Testosterone Cypionate

Testosterone Cypionate  Depo-Testosterone Daviss Drug Guide

Both options are supplied in 100 mg/mL (10 mL) and 200 mg/mL (1 and 10 mL) concentrations, prepared in cottonseed oil. The USA FDA recommended starting dose for male hypogonadism is 50 to 400 mg IM every 2 to 4 weeks (41). The Endocrine Society Clinical Practice Guidelines for testosterone therapy suggest an alternative of either 75 to 100 mg IM weekly or 150 to 200 mg IM every 2 weeks (3). The efficacy of the transdermal patch is often limited by lack of adherence or discontinuation due to skin blistering, pruritus, or irritation. This is due to permeation enhancers included in the transdermal system which are necessary to increase absorption.

In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements. Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.

Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs). Currently the routes of delivery approved for use by the United States Food and Drug Administration encompasses buccal, nasal, subdermal, transdermal, and intramuscular (IM). Many factors must be considered when a clinician is choosing the most correct formulation for a patient. As this decision depends highly on the patient, active patient participation is important for effective selection.

Observed mean range of changes in selected measurable outcomes of testosterone administration to hypogonadal men in reviewed studies. Whether you have health insurance or not, cost may be a factor when you’re considering testosterone cypionate. What you’ll pay for testosterone cypionate may depend on several things, such as your treatment plan and the pharmacy you use. The drug can cause bones to mature more quickly than usual without causing an increase in height. If your child uses this drug, their doctor will check their growth regularly. Testosterone cypionate can interact with several other medications. For instance, some can interfere with how much testosterone do bodybuilders take a week well a drug works, while others can cause increased side effects.

Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

The FDA has only approved testosterone for hypogonadism in cases where it is the result of an underlying medical condition rather than aging. Women should inform their care team if they wish to become pregnant or think they might be pregnant. There is a potential for serious side effects to an unborn child. Talk with your care team about your birth control options while taking this medication. If you have diabetes, check with your care team before you change your diet or the dose of your diabetic medication. Talk to your medical provider about testosterone tablets, gels, or patches. The upfront cost may be more, but these forms don’t involve additional fees for the injection.

Testosterone was in use in 1938 and approved by the FDA in 1939. Anabolic steroids, derivatives of testosterone, have been used illicitly and are now controlled substances. Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in regular and delayed-release (depot) dosage forms. In September 1995, the FDA initially approved testosterone transdermal patches (Androderm); many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA approved in July 2003; the system is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation (Natesto).

It is best to be aware of the possible complications of testosterone injections. Doctors should do a thorough evaluation and, if testosterone replacement therapy is an option, discuss the benefits and risks with the person before prescribing it. This medication is only approved for use in men who have low levels of testosterone related to certain medical conditions. Heart attacks and strokes have been reported with the use of this medication. Talk to your care team about the risks and benefits of this medication. The fluctuation in serum testosterone levels can result in mood swings or changes in libido, which is a formulation specific IM adverse effect that should be closely monitored.